Olema Oncology to Showcase Preclinical Data for Palazestrant and OP-3136 at AACR 2026
Event summary
- Olema Oncology will present two preclinical posters at the 2026 AACR Annual Meeting on April 20.
- Posters focus on Palazestrant's mechanism of action and its synergy with OP-3136 in breast cancer models.
- Palazestrant is in two Phase 3 clinical trials, with FDA Fast Track designation for ER+/HER2- metastatic breast cancer.
- OP-3136 is in a Phase 1 clinical study, with IND application cleared by the FDA in December 2024.
The big picture
Olema Oncology's presentation at AACR 2026 highlights its focus on advancing targeted therapies for breast cancer. The company's dual approach with Palazestrant and OP-3136 aligns with the industry trend towards combination therapies to overcome resistance in ER+ breast cancer. The strategic significance lies in Olema's ability to leverage preclinical data to accelerate clinical development and potentially secure regulatory approvals.
What we're watching
- Clinical Efficacy
- How the preclinical data will translate into clinical outcomes for Palazestrant and OP-3136.
- Regulatory Progress
- The pace at which Palazestrant advances through Phase 3 trials and potential FDA approval.
- Combination Therapy
- Whether the synergy between Palazestrant and OP-3136 can be replicated in human trials.
Related topics